320-x-100_uti_gold.jpg" alt="Advertisement">
Granules India gains after USFDA completes surveillance inspection at Jeedimetla facility with zero observations
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Granules India is currently trading at Rs. 288.75, up by 1.20 points or 0.42% from its previous closing of Rs. 287.55 on the BSE.
The scrip opened at Rs. 287.55 and has touched a high and low of Rs. 290.50 and Rs. 281.40 respectively. So far 56630 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 238.05 on 23-Jun-2022.
Last one week high and low of the scrip stood at Rs. 297.50 and Rs. 281.40 respectively. The current market cap of the company is Rs. 6928.47 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.93% and 29.05% respectively.
US Food & Drug Administration (USFDA) has successfully completed surveillance inspection at Granules India’s Jeedimetla facility located at Hyderabad, Telangana, India from June 19, 2023 to June 23, 2023 with zero (0) 483 observations. Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
